共 50 条
Efficacy of intranasal corticosteroids on the ocular symptoms of allergic rhinitis
被引:1
|作者:
Demoly, P.
[1
]
Klossek, J. M.
[2
]
Serrano, E.
[3
]
Didier, A.
[4
]
机构:
[1] CHU Montpellier, Hop Arnaud de Villeneuve, INSERM, Serv Pneumol & Allergol,U657, F-34295 Montpellier 05, France
[2] CHU Poitiers, Hop Jean Bernard, Serv ORL, F-86021 Poitiers, France
[3] Hop Larrey, Serv ORL, F-31059 Toulouse 9, France
[4] CHU Toulouse, Hop Larrey, Serv Pneumol Allergol, F-31059 Toulouse 9, France
来源:
关键词:
Allergic rhinitis;
Ocular symptoms;
Intranasal corticotherapy;
Furoate;
FUROATE NASAL SPRAY;
FLUTICASONE FUROATE;
SUBLINGUAL IMMUNOTHERAPY;
RECEPTOR ANTAGONISTS;
DOUBLE-BLIND;
SAFETY;
MANAGEMENT;
POLLEN;
PROPIONATE;
CHALLENGE;
D O I:
10.1016/j.reval.2010.03.002
中图分类号:
R392 [医学免疫学];
学科分类号:
100102 ;
摘要:
Allergic rhinitis (AR) is the most prevalent allergic disease. AR seriously affects the quality of life of patients who suffer from this condition, and it also affects their professional and social activities. Ocular symptoms represent a major component of AR and their importance is often underestimated. The pathophysiology of the ocular symptoms of AR has been studied extensively over the last decade. Intranasal corticosteroids are without a doubt effective in alleviating these ocular symptoms. Mometasone furoate and fluticasone furoate nasal sprays, in particular, are two new topically-active corticosteroids whose efficacy on ocular symptoms has been demonstrated in prospective studies in patients with seasonal and/or perennial AR. Drug treatment of AR can therefore be based on the administration of intranasal corticosteroid which, when combined with allergen avoidance and eye washes, should provide optimal benefit while minimizing cost and pharmaceutical risks. (C) 2010 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:419 / 425
页数:7
相关论文